NVIDIA · 3 weeks ago
Senior Solutions Architect - Drug Discovery
NVIDIA is seeking a Senior Solutions Architect to help redefine drug discovery and biological research through GPU-accelerated AI. This role will focus on enabling pharmaceutical and techbio customers to train, optimize, and deploy large biological foundation models using NVIDIA’s accelerated computing platform.
Artificial Intelligence (AI)TransportationCloud ComputingEmbedded SoftwareGamingHardwareQuantum ComputingSemiconductorAI InfrastructureAutonomous VehiclesEmbedded SystemsFoundational AI
Responsibilities
Partner with business and account teams to understand customer goals, scientific workflows, technical needs, and platform adoption strategies
Architect and optimize AI/ML pipelines for training large biological foundation models, with a focus on BioNeMo libraries and GPU-accelerated software that improve training efficiency
Build proof-of-concept demonstrations that show how NVIDIA software and hardware accelerate scientific discovery
Collaborate across NVIDIA with subject matter experts, engineering, product, and field teams to bring the right technical expertise to customer engagements and deliver high-impact solutions
Document best practices and teach others through technical enablement, partner training, whitepapers, blogs, internal wiki articles, and hands-on customer workshops
Serve as a trusted technical advisor for integrating NVIDIA technologies into advanced biopharma and diagnostics applications
Qualification
Required
MS or PhD in Computational Biology, Computational Chemistry, Computational Physics, Chemical Engineering, Biophysics, Computer Science, or a related technical field (or equivalent experience)
8+ years of experience in software development for deep learning, GPU acceleration, or scientific computing applications
Hands-on experience applying ML to at least one of these domains: genomics, quantum chemistry, biomaterials science, or structural biology
Experience profiling and optimizing training workflows for large AI models, including performance tuning, distributed training, data pipelines, and GPU utilization
Proficiency with Linux environments and experience working in HPC or accelerated computing environments, including Slurm and/or Kubernetes-based clusters
Excellent communication skills, especially for presenting highly technical material to scientists, engineers, executives, and customer stakeholders
A passion for working with forward-thinking customers, learning continuously, and staying at the forefront of AI for life sciences
Preferred
Background with BioNeMo, NeMo, or related NVIDIA frameworks for training large biological or scientific foundation models
Experience with Parabricks, RAPIDS-singlecell, ALCHEMI, cuEquivariance, cuEST, or related accelerated libraries
Experience working with pharmaceutical or biotech companies
Demonstration of customer-facing technical leadership, including architecture reviews, executive briefings, technical workshops, or deployments at lighthouse accounts
Benefits
You will also be eligible for equity and [benefits](https://www.nvidia.com/en-us/benefits/).
Company
NVIDIA
NVIDIA is a computing platform company operating at the intersection of graphics, HPC, and AI.
H1B Sponsorship
NVIDIA has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
89%
Represents job field similar to this job
Engineering and Development
Management and Executive
Product Management
Marketing
Sales
Accounting and Finance
Customer Service and Support
Creatives and Design
Human Resources
Arts and Entertainment
Legal and Compliance
Trends of Total Sponsorships
*2026 (1247)
2025 (1868)
2024 (1353)
2023 (976)
2022 (835)
2021 (601)
2020 (529)
Funding
Current Stage
Public CompanyTotal Funding
$29.09BKey Investors
ARPA-EARK Investment ManagementSoftBank Vision Fund
2026-06-15Post Ipo Debt· $25B
2023-05-09Grant· $5M
2022-08-09Post Ipo Equity· $65M
Recent News
2026-08-09
2026-08-09
2026-08-09
Company data provided by crunchbase